13.7 Use Of Information And Publication 
All information concerning Avectin™ and the sponsor's 
operation, such as patent applications, formulas, manufacturing 
processes, and basic scientific data supplied by the sponsor and 
not previously published are considered confidential and shall 
remain the sole property of the sponsor. The investigator agrees 
to use this information only in accomplishing this study and 
will not use it for other purposes without the sponsor's written 
consent. 
It is understood by the investigator that the data developed in 
this clinical study is the property of the sponsor and will be used 
by the sponsor in connection with the development of 
Avectin™ and, therefore, may be disclosed as required to other 
clinical investigators, the FDA and other government agencies, 
and to foreign regulatory authorities. 
The investigator may not publish study data prior to complete 
patient enrollment. The sponsor must approve all abstracts and 
manuscripts at least 30 days prior to submission for publication. 
14.0 REFERENCES 
1. Berd, D., Maguire, H.C., Jr., Mastrangelo, M.J. Induction of cell- 
mediated immunity to autologous melanoma cells and regression of 
metastases after treatment with a melanoma cell vaccine preceded by 
cyclophosphamide. Cancer Res. 1986; 46: 2572-2577. 
2. McCune, C.S., Schapira, D.V., Henshaw, E.C. Specific immunotherapy 
of advanced renal carcinoma: Evidence for the polyclonality of 
metastases. Cancer 1981; 47: 1984-1987. 
3. Neidhart, J.A., Murphy, S.G., Hennick, L.A., Wise, H.A. Active specific 
immunotherapy of stage IV renal carcinoma with aggregated tumor 
antigen adjuvant. Cancer 1980; 46: 1128-1134. 
4. Hoover, H.C., Jr., Surdyke, M.G., Dangel, R.B., Peters, L.C., Hanna, M., 
Jr. Prospectively randomized trial of adjuvant active-specific 
immunotherapy for human colorectal cancer. Cancer 1985; 55: 1236- 
1243. 
5. Mitchell, M.S., Harel, W., Kempf, R.A., Hu, E., Kan-Mitchell, J., Dean, 
G., Moore, J. Active specific immunotherapy for melanoma. J. Clin. 
Oncol. 1990, 8: 1-13. 
6. Seigler, H.F., Cox, E., Mutzner, F., Shepherd, L., Nicholson, E., 
Shingleton, W.W. Specific active immunotherapy for melanoma. 
Ann. Surg. 1979, 190: 366-372. 
7. Cox, E.B., Vollmer, R., Seigler, H.F. Melanoma in the Southeastern 
United States: Experience at the Duke Medical Center, in Cutaneous 
Melanoma: Clinical Management and Treatment Results Worldwide : 
[ 264 ] 
Recombinant DNA Research, Volume 20 
